Eli Lilly is expanding its GLP-1 research to cover hypertension and neurological conditions. The pharmaceutical company aims to explore new therapeutic applications for its groundbreaking GLP-1 receptor agonists.
Future of Eli Lilly Research
Eli Lilly has made waves with its GLP-1 drugs, including tirzepatide, under the brand names of Zepbound and Mounjaro. Initially for diabetes and weight loss, these drugs now show promise for other conditions.
Recent studies suggest that GLP-1 receptor agonists may significantly reduce blood pressure in patients with hypertension. As a result, this development has prompted Eli Lilly to explore new treatment possibilities.
According to STAT News, Eli Lilly also plans to start a Phase 3 trial of its GLP-1 drug orforglipron in treating hypertension. In addition, the pharmaceutical company intends to do research on incretin drugs. Specifically, it aims to study its potential in addressing pain, brain health, and neuropsychiatry. Incretin drug treatments specifically target hormones such as GLP-1 and GIP.
Eli Lilly GLP-1 Drug Tirzepatide
GLP-1 receptor agonists mimic a hormone that regulates blood sugar, appetite, and metabolism. These drugs slow digestion, improve insulin sensitivity, and promote weight loss. Tirzepatide, Eli Lilly’s dual GIP and GLP-1 receptor agonist, takes these benefits further by enhancing appetite control and metabolic health.
The same mechanisms that aid in weight management may also play a role in reducing hypertension. Notably, weight loss contributes to lower blood pressure, while better insulin sensitivity supports better cardiovascular health. Eli Lilly researchers believe these effects could translate into significant benefits for people with high blood pressure.
Potential Brain Benefits
Beyond hypertension, researchers apart from Eli Lilly are investigating GLP-1 drugs for neurological disorders. Scientists from the Washington University School of Medicine and the Veterans Affairs St. Louis Health Care System have reported that GLP-1 drugs Ozempic and Wegovy could benefit addiction and reward-related behaviors. If confirmed, this could open a new frontier in neurological care.
The potential for GLP-1 drugs in neurology is particularly exciting. Scientists are investigating their effects on cognitive health, with some studies suggesting a reduced risk of Alzheimer’s disease. In particular, GLP-1 receptor activation may protect brain cells from damage, reducing inflammation and improving neural function.
Additionally, researchers are examining how these drugs could help patients with neurodegenerative diseases. If proven effective, GLP-1 receptor agonists could revolutionize treatments for Alzheimer’s and other cognitive disorders. Further trials from Eli Lilly and other companies will determine their long-term impact on neurological health.
Challenges and Risks
Despite their promise, GLP-1 drugs come with potential risks. Common side effects include nausea, vomiting, and gastrointestinal discomfort. Some studies have also raised concerns about kidney function in certain patients. As Eli Lilly expands its research, careful monitoring will be crucial to ensure safety.
Moreover, the long-term effects of GLP-1 drugs on the brain remain unclear. While early results are encouraging, more extensive trials are necessary to confirm their benefits. Scientists must also determine the appropriate dosing for neurological and cardiovascular conditions.
Eli Lilly’s expansion of GLP-1 research marks a significant shift in drug development. Its efforts could lead to groundbreaking treatments that improve lives worldwide.
Image by freepik
